A Look at Orphan Drug Development in Retina

The regulatory pathway has matured, and the commercial and reimbursement lessons have sharpened.

Thomas A. Ciulla, MD, MBA

Rare Disease Mystery Cases

Can you diagnose these unusual cases based on the examination and imaging?

Kenneth C. Fan, MD, MBA; Caroline C. Awh, MD; Nimesh A. Patel, MD; Marta Stevanovic, MD, MSc; Maria Emfietzoglou, MD; Demetrios Vavvas, MD, PhD; Mary V. Lang; Lisa A. Schimmenti, MD; Brittni A. Scruggs, MD, PhD; Yicheng Bao, MD; and Hossein Ameri, MD, PhD, FRCSI, MRCOphth

Patient Diversity in ROP Trials

A novel analysis reveals the racial and ethnic representation across retinopathy of prematurity clinical trials from 1995 to 2023.

Yannet Daniel, BS; Xiru Lyu, MS; Cagri Besirli, MD, PhD; and Emily Eton, MD

Genetic Testing in the Retina Practice

What’s changing and why it matters.

Timothy S. Lee, MD; Eric W. Lai, MD; and Sidney A. Schechet, MD